wedge
wedge
wedge Biotrofix wedge The Company
wedge wedge wedge wedge wedge
 
Home
greybar
The Company
greybar
Preclinical Research Services
Acute Stroke
Stroke Recovery
Alzheimer's Disease
Amyotrophic Lateral Sclerosis
Traumatic Brain Injury
Spinal Cord Injury
Muscular Dystrophy
Myocardial Infarction
Peripheral Vascular Disease
Others
Will Travel Services
greybar
The Team
greybar
Publications
greybar
Contact Us


Well-equipped CRO laboratory
 

Seth P. Finklestein, M.D., CEO
Seth P. Finklestein, M.D., CEO is former Associate Professor of Neurology at Harvard Medical School/Massachusetts General Hospital (HMS/MGH) and former Director of the NIH-funded CNS Growth Factor Research Laboratory at MGH. From 2001-2004, he was V.P. and Head of the Neuroscience Division at Viacell, Inc., before founding Biotrofix. Dr. Finklestein has more than 20 years of experience in animal models of neurological disease. He is the author of over 140 peer-reviewed research publications and review articles, and inventor on 7 issued patents and patent applications. He is a graduate of Haverford College and Harvard Medical School.
JingMei Ren, M.D., Vice President, Preclinical Development
JingMei Ren, M.D., Vice President, Preclinical Development, has worked with Dr. Finklestein for more than 10 years and is co-author with him on numerous research publications. She is widely experienced in animal models of neurological diseases. Mei received her M.D. from the Capital Institute of Medicine, in Beijing, China.
Charlie Popkin, Chief Financial Officer

Charlie Popkin, Chief Financial Officer, Prior to joining Biotrofix Charlie was the CFO of The Merallis Company, a healthcare technology services firm. Charlie past experiences also include serving as a founding management member of PQC, Inc., a management services company, founding Medical Claims Management (MCM), a practice reimbursement management and consulting firm and working as a Senior Consultant for Price Waterhouse and as Senior Accountant for Deloitte & Touche. Charlie is a CPA, has a B.S. in Accountancy an A.S. in Management from Bentley College and an M.M. in Finance and Business Policy from the J.L. Kellogg School at Northwestern University.

   
Jeffrey S. Davis, Chief Marketing Officer

Jeffrey S. Davis, Chief Marketing Officer, formally worked for Fortune 100 and 500 organizations, including Johnson & Johnson and Athena Diagnostics before founding Mage in 1985. Davis is the founder and chairman of Mage management consulting and family business advisory in Boston, assisting over 700 clients to date. He is the New England Chairman of The Board of the Jewish National Fund (JNF) and serves as an Assistant Vice President on the JNF's National Board of Directors. He is also a founding member of the Massachusetts Family Business Awards and an Executive Director of the Family Business Association. Davis is a graduate of Concordia University in Montreal and the University of Ottawa.

   
Dana K. Sietsma, Director of Operations
Dana K. Sietsma, Director of Operations, manages the daily operations of Biotrofix, specifically in the areas of program management, marketing, and quality assurance. Dana has worked with Drs. Finklestein and Ren since 1999, first at the Massachusetts General Hospital and then at Viacell, Inc. Dana then worked as an administrator at the Marine Biological Laboratory, and joined Biotrofix in 2006. She holds a B.S. in Biology (with a minor in Psychology) from Bridgewater State College.
Roz Switalski, Director of Finance
Roz Switalski, Director of Finance, has over 10 years of experience in finance and administration. Roz has worked in information technology, biotechnology, as well as various other industries. Roz began working with Biotrofix in 2006, and is responsible for financial management and all aspects of human resources. Roz holds a B.A. from Rutgers University and an M.B.A from Babson College.
Angel Som, Research Associate
Angel Som, Research Associate, assists in all aspects of preclinical studies, especially in drug administration and behavioral evaluations. Prior to joining Biotrofix, she obtained a B.S. in Biology (with a minor in Chemistry) from Simmons College. While there, Angel completed her senior thesis on the proliferation and differentiation of progenitor cells in the subventricular zone of the rat brain.
Nicole Green, Director of Client Relations
Nicole Green, Director of Client Relations, has 12 years of experience in the scientific and business aspects of the biotech industry. She has worked as a Molecular Biologist at Wyeth, Sanofi-Aventis, and Novartis. At CombinatoRx, she was Staffing Manager in the Human Relations Department, and, most recently, she was an Executive Search Consultant for Positions, Inc., working in the biopharmaceutical sector. Nicole holds a B.S. in Chemistry from Emmanuel College.
   

 

 
 
Home | The Company | Preclinical CRO Services | The Team | Publications | Contact Us | Site Map
wedgeBiotrofix, Inc.830 Winter Street, 1st floor, Waltham, MA 02451Tel: 781-314-9300Fax: 781-465-6061


Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.